XML 60 R42.htm IDEA: XBRL DOCUMENT v3.22.4

Equity (Tables)

12 Months Ended

Dec. 31, 2022

Summary of Stock Option Activity

A summary of the status of the options granted by Teva as of December 31, 2022, 2021 and 2020, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof).

		Year ended December 31,
		2022								2021								2020
		Number (in thousands)				Weighted average exercise price				Number (in thousands)				Weighted average exercise price				Number (in thousands)				Weighted average exercise price
Balance outstanding at beginning of year			29,015			$	36.96				35,234			$	37.27				40,064			$	37.90
Changes during the year:
Forfeited			(2,378	)			33.77				(3,644	)			36.09				(3,610	)			40.24
Expired			(2,518	)			41.26				(2,575	)			42.40				(1,220	)			49.35
Balance outstanding at end of year			24,119				36.83				29,015				36.96				35,234				37.27
Balance exercisable at end of year			24,119				36.83				26,989				38.30				28,556				40.56

No options were granted during 2022, 2021 and 2020.

Schedule of Ordinary Shares Issued Upon Vested Options

The following table summarizes information as of December 31, 2022 regarding the number of ordinary shares issuable upon vested options:

Number of ordinary shares issuable upon exercise of vested options
Range of exercise prices		Balance at end of period (in thousands)				Weighted average exercise price				Weighted average remaining life
		Number of shares				$				Years
Lower than $15.01			592				11.40				4.84
$15.01 - $25.00			7,781				18.96				5.13
$25.01 - $35.00			5,712				34.61				4.16
$35.01 - $45.00			509				38.13				0.57
$45.01 - $55.00			5,906				51.30				2.36
$55.01 - $65.00			3,619				59.10				2.33
Total			24,119				36.83				3.70

Schedule of the Number of RSUs Issued and Outstanding

The following table summarizes information about the number of RSUs and PSUs granted and outstanding:

		Year ended December 31,
		2022								2021								2020
		Number (in thousands)				Weighted average grant date fair value				Number (in thousands)				Weighted average grant date fair value				Number (in thousands)				Weighted average grant date fair value
Balance outstanding at beginning of year			24,412			$	11.58				20,720			$	13.81				15,977			$	16.49
Granted			18,755				7.42				12,748				10.42				10,848				11.42
Vested			(7,571	)			13.02				(6,818	)			15.60				(4,324	)			19.49
Forfeited			(3,293	)			9.81				(2,238	)			12.18				(1,781	)			18.18
Balance outstanding at end of year			32,302				9.11				24,412				11.58				20,720				13.81

Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value

The Company expenses compensation costs are based on the grant-date fair value. For the years ended December 31, 2022, 2021 and 2020, the Company recorded stock-based compensation costs as follows:

		Year ended December 31,
		2022				2021				2020
		(U.S. $ in millions)
Employee stock options		$	2			$	16			$	30
RSUs and PSUs			122				103				99
Total stock-based compensation expense			124				119				129
Tax effect on stock-based compensation expense			9				12				14
Net effect		$	115			$	107			$	115

Accumulated Other Comprehensive Income/(Loss) (Net of Tax)

The components of accumulated other comprehensive loss attributable to Teva are presented in the table below:

		Net Unrealized Gains/(Losses)								Benefit Plans
		Foreign currency translation adjustments				Derivative financial instruments				Actuarial gains/(losses) and prior service (costs)/credits				Total
		(U.S. $ in millions)
Balance as of January 1, 2020		$	(1,794	)			(420	)			(98	)			(2,312	)
Other comprehensive income/(loss) before reclassifications			(190	)			22				(7	)			(175	)
Amounts reclassified to the statements of income			—				35				(12	)			23
Net other comprehensive income/(loss) before tax			(190	)			57				(19	)			(152	)
Corresponding income tax			65				—				1				66
Net other comprehensive income/(loss) after tax*			(125	)			57				(18	)			(86	)
Balance as of December 31, 2020			(1,919	)			(363	)			(117	)			(2,399	)
Other comprehensive income/(loss) before reclassifications			(386	)			—				18				(368	)
Amounts reclassified to the statements of income			—				39				18				57
Net other comprehensive income/(loss) before tax			(386	)			39				36				(311	)
Corresponding income tax			31				—				(4	)			27
Net other comprehensive income/(loss) after tax*			(355	)			39				32				(284	)
Balance as of December 31, 2021			(2,274	)			(324	)			(85	)			(2,683	)
Other comprehensive income/(loss) before reclassifications			(223	)			—				40				(183	)
Amounts reclassified to the statements of income			—				29				27				56
Net other comprehensive income/(loss) before tax			(223	)			29				67				(127	)
Corresponding income tax			(17	)			—				(10	)			(27	)
Net other comprehensive income/(loss) after tax*			(240	)			29				57				(154	)
Balance as of December 31, 2022		$	(2,514	)		$	(295	)		$	(28	)		$	(2,838	)

* Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $116 million loss in 2022, $107 million loss in 2021 and $56 million gain in 2020.

X

- Definition

Tabular disclosure of share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of accumulated other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

+ Details

Name:	us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration